$294.56 Million in Sales Expected for RadNet, Inc. (NASDAQ:RDNT) This Quarter

Last updated on Monday, April 19, 2021 | 2021 MarketBeat

Equities analysts expect that RadNet, Inc. (NASDAQ:RDNT) will post $294.56 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for RadNet's earnings, with estimates ranging from $292.81 million to $296.31 million. RadNet reported sales of $281.56 million in the same quarter last year, which indicates a positive year-over-year growth rate of 4.6%. The company is expected to issue its next earnings report on Monday, May 10th.

According to Zacks, analysts expect that RadNet will report full year sales of $1.28 billion for the current year. For the next year, analysts forecast that the firm will report sales of $1.34 billion, with estimates ranging from $1.33 billion to $1.34 billion. Zacks' sales averages are a mean average based on a survey of sell-side analysts that follow RadNet.

RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Sunday, March 7th. The medical research company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.04). RadNet had a negative net margin of 0.98% and a negative return on equity of 2.72%. The company had revenue of $308.50 million for the quarter, compared to analysts' expectations of $300.62 million. During the same period in the previous year, the firm earned $0.21 earnings per share. The firm's revenue for the quarter was up 2.6% on a year-over-year basis.

Separately, Raymond James lifted their price objective on RadNet from $22.00 to $26.00 and gave the stock an "outperform" rating in a report on Monday, March 15th.

In other news, SVP Ruth Louisa Villigerwilson sold 2,500 shares of the business's stock in a transaction dated Wednesday, March 10th. The stock was sold at an average price of $22.97, for a total value of $57,425.00. Following the transaction, the senior vice president now directly owns 31,914 shares in the company, valued at $733,064.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Norman R. Hames sold 35,000 shares of the company's stock in a transaction that occurred on Monday, March 8th. The stock was sold at an average price of $21.00, for a total value of $735,000.00. Following the completion of the transaction, the insider now owns 370,160 shares of the company's stock, valued at $7,773,360. The disclosure for this sale can be found here. Insiders have sold 92,500 shares of company stock valued at $2,027,575 over the last 90 days. 5.77% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in shares of RadNet by 2.5% in the 4th quarter. BlackRock Inc. now owns 6,540,626 shares of the medical research company's stock valued at $128,000,000 after purchasing an additional 156,933 shares during the last quarter. Beck Mack & Oliver LLC lifted its position in RadNet by 4.3% in the fourth quarter. Beck Mack & Oliver LLC now owns 2,027,466 shares of the medical research company's stock worth $39,678,000 after buying an additional 82,851 shares during the last quarter. Tamarack Advisers LP boosted its stake in RadNet by 4.0% during the fourth quarter. Tamarack Advisers LP now owns 650,000 shares of the medical research company's stock worth $12,093,000 after buying an additional 25,000 shares during the period. SummerHaven Investment Management LLC bought a new position in RadNet during the fourth quarter valued at $528,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of RadNet by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 282,529 shares of the medical research company's stock valued at $5,530,000 after acquiring an additional 2,369 shares during the period. Institutional investors and hedge funds own 67.46% of the company's stock.

Shares of RDNT opened at $22.21 on Monday. The firm has a fifty day simple moving average of $21.54 and a two-hundred day simple moving average of $19.06. The firm has a market cap of $1.16 billion, a PE ratio of -105.80 and a beta of 1.52. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 2.55. RadNet has a 1-year low of $11.27 and a 1-year high of $25.49.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Article: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on RadNet (RDNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Forex

7 Low-Priced Dividend Stocks Under $10

The recent trading activity surrounding low-priced stocks like GameStop (NYSE:GME) is a reminder to investors of the high-risk nature involved with these stocks. Often when a stock trades for under $10 (also termed a penny stock), it is trading that low for a reason. The company may not be profitable, or in the case of GameStop, it finds itself with a business model that no longer fits with consumer trends.

But that’s not always the case. It is possible to find low-priced stocks, even penny stocks, that offer great value. This is particularly true if the stock offers investors a dividend. Dividend-earning stocks are a diversification source for a consumer’s portfolio, particularly if the dividend gets reinvested. It’s literally like paying yourself for owning the stock.

And the stocks in this presentation look ready also to deliver some additional stock price growth that can increase your total return.

View the "7 Low-Priced Dividend Stocks Under $10".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.